AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38919489 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients with three comorbid conditions
Number of subjects: 25454
Study 38919489 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients with four or more comorbid conditions
Number of subjects: 25454
Study 38919489 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity burden in relation to diabetes duration
Number of subjects: 25454
Study 38919489 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity burden by age group
Number of subjects: 25454
Study 38919489 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity prevalence by gender
Number of subjects: 25454
Study 38919489 — intervention group
Group type: EXPERIMENTAL
Intervention: Most common comorbid conditions in T2DM patients
Number of subjects: 25454
Study 38919489 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-prevalence of comorbid conditions
Number of subjects: 25454
Study 38919520 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive intracranial pressure (ICP) monitoring using distortion product otoacoustic emissions (DPOAE)
Number of subjects: 125
Study 38919522 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-based induction chemotherapy followed by radiotherapy (IC+RT)
Number of subjects: 52
Study 38919522 — intervention group
Group type: COMPARATOR
Intervention: TL followed by postoperative radiotherapy (TL+PORT)
Number of subjects: 52
Study 38919522 — intervention group
Group type: COMPARATOR
Intervention: TL followed by postoperative radiochemotherapy (TL+PORCT)
Number of subjects: 52
Study 38919522 — intervention group
Group type: COMPARATOR
Intervention: cisplatin-based concurrent radiochemotherapy (CRT)
Number of subjects: 52
Study 38919799 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 48
Study 38919799 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Aerobics (WA)
Number of subjects: 48
Study 38919799 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (WA and MCT)
Number of subjects: 48
Study 38919799 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 38919826 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab (PDR001) 300 mg intravenous every three weeks until disease progression or unacceptable toxicity
Number of subjects: 44
Study 38919921 — intervention group
Group type: EXPERIMENTAL
Intervention: START NOW Adapted
Number of subjects: 80
Study 38919921 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 80
Study 38920297 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir plus standard of care (SOC)
Number of subjects: 3399
Study 38920297 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 3399
Study 38920407 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (300 mg QDAY by mouth on days 1-5 and 8-12 of each 21-day cycle)
Number of subjects: 18
Study 38920618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-Protective Mechanical Ventilation (LPMV) protocol
Number of subjects: 693
Study 38920618 — intervention group
Group type: COMPARATOR
Intervention: Standard care (non-LPMV)
Number of subjects: 693
Study 38920618 — intervention group
Group type: EXPERIMENTAL
Intervention: LPMV protocol
Number of subjects: 693
Study 38920618 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to LPMV strategies
Number of subjects: 693
Study 38920618 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to PIP, DP, and PEEP/F io2 combinations
Number of subjects: 693
Study 38921304 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (dancing and resistance exercises, nutritional education)
Number of subjects: 12
Study 38921720 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenursing intervention for PICC management (experimental group)
Number of subjects: 72
Study 38921720 — intervention group
Group type: COMPARATOR
Intervention: Outpatient dressing for PICC at the hospital (control group)
Number of subjects: 72
Study 38921800 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirsevimab (50 mg for <5 kg, 100 mg for ≥5 kg, 200 mg for second season)
Number of subjects: 0
Study 38921800 — intervention group
Group type: COMPARATOR
Intervention: Palivizumab (5× once-monthly)
Number of subjects: 0
Study 38921800 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirsevimab (200 mg for re-randomized first-season palivizumab recipients)
Number of subjects: 0
Study 38922218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (6 sessions)
Number of subjects: 13
Study 38922218 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (6 sessions)
Number of subjects: 13
Study 38922307 — intervention group
Group type: EXPERIMENTAL
Intervention: sacituzumab govitecan + pembrolizumab
Number of subjects: 0
Study 38922307 — intervention group
Group type: COMPARATOR
Intervention: pembrolizumab (± capecitabine)
Number of subjects: 0
Study 38922306 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-led, home-based early intervention for motor development, engaging in multidomain stimulation activities five days a week for six months
Number of subjects: 0
Study 38922306 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38922428 — intervention group
Group type: EXPERIMENTAL
Intervention: Freestyle Libre pro IQ sensor (blinded continuous glucose monitoring) for 14 days
Number of subjects: 29
Study 38922435 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation home program (TRP) in addition to pharmaceutical treatment
Number of subjects: 400
Study 38922435 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical treatment (Control)
Number of subjects: 400
Study 38922484 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg every 2 weeks
Number of subjects: 0
Study 38922488 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated risk factor time path equations
Number of subjects: 28608
Study 38922488 — intervention group
Group type: COMPARATOR
Intervention: Original risk factor time path equations
Number of subjects: 28608
Study 38922520 — intervention group
Group type: EXPERIMENTAL
Intervention: DKP/TRAM 25/75 mg every 8 h (n=211)
Number of subjects: 538
Study 38922577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) combined with high-intensity interval training (HIIT)
Number of subjects: 36
Study 38922577 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting (IF) alone
Number of subjects: 36
Study 38922577 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) alone
Number of subjects: 36
Study 38922577 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 38922618 — intervention group
Group type: EXPERIMENTAL
Intervention: Chat-based cessation support delivered by a live counselor via a mobile instant messaging app for 3 months from baseline.
Number of subjects: 624
Study 38922632 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine functional testing
Number of subjects: 1706
Study 38922632 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 1706
Study 38922689 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice Weekly Hemodialysis
Number of subjects: 0
Study 38922689 — intervention group
Group type: COMPARATOR
Intervention: Thrice Weekly Hemodialysis
Number of subjects: 0
Study 38922906 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day DHA supplementation during pregnancy (PGO-800)
Number of subjects: 169
Study 38922906 — intervention group
Group type: COMPARATOR
Intervention: 200 mg/day DHA supplementation during pregnancy (PGO-200)
Number of subjects: 169
Study 38922990 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with recombinant FIX Fc fusion protein (rFIXFc), n=11
Number of subjects: 33
Study 38922990 — intervention group
Group type: COMPARATOR
Intervention: On demand (OD) treatment with rFIXFc, n=22
Number of subjects: 33
Study 38923102 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized intraosseous anesthesia (CIOA) using QuickSleeper 5
Number of subjects: 88
Study 38923102 — intervention group
Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block (IANB)
Number of subjects: 88
Study 38923140 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based guideline-directed medical therapy (GDMT)
Number of subjects: 2500
Study 38923140 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity treatment
Number of subjects: 2500
Study 38923140 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequence of treatment introduction and up-titration
Number of subjects: 2500
Study 38923140 — intervention group
Group type: EXPERIMENTAL
Intervention: GDMT implementation
Number of subjects: 2500
Study 38923140 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of GDMT underuse
Number of subjects: 2500
Study 38923140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative rate of cardiovascular events
Number of subjects: 2500
Study 38923439 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin prophylaxis from <16 weeks until 36 weeks for high-risk women
Number of subjects: 48725
Study 38923439 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin prophylaxis for high-risk women
Number of subjects: 48725
Study 38923439 — intervention group
Group type: COMPARATOR
Intervention: Screen-and-prevent strategy for preterm preeclampsia
Number of subjects: 48725
Study 38923527 — intervention group
Group type: EXPERIMENTAL
Intervention: Online matching-task (MT) paradigm
Number of subjects: 40
Study 38923743 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger individuals (20-39 years)
Number of subjects: 9848
Study 38923743 — intervention group
Group type: EXPERIMENTAL
Intervention: Older individuals (≥40 years)
Number of subjects: 9848
Study 38923871 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg QD
Number of subjects: 341
Study 38923871 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-599 high dose (elsubrutinib 60 mg and upadacitinib 30 mg QD)
Number of subjects: 341
Study 38923871 — intervention group
Group type: COMPARATOR
Intervention: Placebo QD
Number of subjects: 341
Study 38923871 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib and ABBV-599 high dose
Number of subjects: 341
Study 38923910 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy (TIS+Chemo)
Number of subjects: 0
Study 38923910 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Chemo)
Number of subjects: 0
Study 38923965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine administered twice daily with optical defocus (DIMS lenses)
Number of subjects: 112
Study 38923965 — intervention group
Group type: COMPARATOR
Intervention: 0.01% atropine administered twice daily (single vision lenses)
Number of subjects: 112
Study 38924038 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention (four remote educational sessions)
Number of subjects: 384
Study 38924038 — intervention group
Group type: COMPARATOR
Intervention: Standard educational approach (four in-person sessions)
Number of subjects: 384
Study 38924124 — intervention group
Group type: EXPERIMENTAL
Intervention: Crovalimab
Number of subjects: 89
Study 38924124 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 89
Study 38924169 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Pulmonary Index enabled
Number of subjects: 0
Study 38924169 — intervention group
Group type: COMPARATOR
Intervention: Integrated Pulmonary Index disabled
Number of subjects: 0
Study 38924429 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3152 (600 mg intramuscular injection)
Number of subjects: 0
Study 38924429 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3152 (prophylactic administration)
Number of subjects: 0
Study 38924429 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3152
Number of subjects: 0
Study 38924456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Number of subjects: 1
Study 38924481 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual environment for CVD prevention education
Number of subjects: 25
Study 38924481 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual environment features
Number of subjects: 25
Study 38924481 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatar customization options
Number of subjects: 25
Study 38924481 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk factors
Number of subjects: 25
Study 38924481 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns regarding comorbid conditions
Number of subjects: 25
Study 38924724 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg BID
Number of subjects: 755
Study 38924724 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg QD
Number of subjects: 755
Study 38924724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 755
Study 38924731 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-exposure dupilumab regimen
Number of subjects: 102
Study 38924731 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-exposure dupilumab regimen
Number of subjects: 102
Study 38924731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 38924732 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg subcutaneous every 4 weeks)
Number of subjects: 211
Study 38924732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 38924756 — intervention group
Group type: EXPERIMENTAL
Intervention: Amivantamab-lazertinib
Number of subjects: 1074
Study 38924756 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 1074
Study 38924756 — intervention group
Group type: COMPARATOR
Intervention: Amivantamab-lazertinib vs. Osimertinib
Number of subjects: 1074
Study 38924779 — intervention group
Group type: EXPERIMENTAL
Intervention: Video recording of MDC visit
Number of subjects: 24
Study 38924779 — intervention group
Group type: COMPARATOR
Intervention: Normal after-visit summary (treatment as usual)
Number of subjects: 24
Study 38924855 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction systemic therapy followed by complete local treatment
Number of subjects: 215
Study 38924855 — intervention group
Group type: COMPARATOR
Intervention: RECIST1.1
Number of subjects: 215
Study 38924976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pillow mannequin intervention group (n = 31)
Number of subjects: 61
Study 38924976 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 61
Study 38925110 — intervention group
Group type: EXPERIMENTAL
Intervention: ECoG high gamma signals during speech
Number of subjects: 0
Study 38925354 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP supplementation (two 75-g sachets per day)
Number of subjects: 957
Study 38925354 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP supplementation + Azithromycin (20 mg/kg at 42 days)
Number of subjects: 957
Study 38925354 — intervention group
Group type: COMPARATOR
Intervention: Control (standard-of-care counseling on exclusive breastfeeding, nutrition, infant immunization, and health promotion plus iron-folate supplementation)
Number of subjects: 957
Study 38925586 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg PEG-rhG-CSF
Number of subjects: 122
Study 38925586 — intervention group
Group type: COMPARATOR
Intervention: 6 mg PEG-rhG-CSF
Number of subjects: 122
Study 38925586 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg PEG-rhG-CSF (BW ≤ 60 kg)
Number of subjects: 122
Study 38925586 — intervention group
Group type: COMPARATOR
Intervention: 6 mg PEG-rhG-CSF (BW ≤ 60 kg)
Number of subjects: 122
Study 38925586 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg PEG-rhG-CSF (BW > 60 kg)
Number of subjects: 122
Study 38925586 — intervention group
Group type: COMPARATOR
Intervention: 6 mg PEG-rhG-CSF (BW > 60 kg)
Number of subjects: 122
Study 38925684 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) recordings (24-hour, supine, standing and exercise stress test)
Number of subjects: 153
Study 38925684 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) monitoring
Number of subjects: 153
Study 38925684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function, cardiorespiratory fitness, cardiovascular health, balance and strength assessments
Number of subjects: 153
Study 38925684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessments of exhaustion, mood and tension
Number of subjects: 153
Study 38925688 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable remission (BMI≥18.5 kg/m²)
Number of subjects: 125
Study 38925688 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable remission (BMI<18.5 kg/m²)
Number of subjects: 125
Study 38925688 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=100)
Number of subjects: 125
Study 38925694 — intervention group
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cells (UC-MSCs) treatment
Number of subjects: 150
Study 38925694 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 150
Study 38925694 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs-short group (UC-MSCs)
Number of subjects: 150
Study 38925694 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCs-prolonged group (UC-MSCs)
Number of subjects: 150
Study 38925705 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation programme including exercise training, nutritional optimisation, and psychological support.
Number of subjects: 25
Study 38925705 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation programme (exercise training with a certified kinesiologist, nutritional optimisation with a registered dietician, psychological support with a nurse specialist).
Number of subjects: 25
Study 38925705 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training on a cycle ergometer as part of the exercise training programme.
Number of subjects: 25
Study 38925705 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplantation outcomes will be recorded.
Number of subjects: 25
Study 38925712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PENG block with 18 mL of 0.5% ropivacaine mixed with 2 mL of a contrast agent
Number of subjects: 10
Study 38925712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PENG block
Number of subjects: 10
Study 38925731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual and reproductive health services
Number of subjects: 1743
Study 38925731 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support
Number of subjects: 1743
Study 38925803 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily on days 1-3, followed by 0.5 mg daily thereafter)
Number of subjects: 8343
Study 38925803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8343
Study 38925803 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 8343
Study 38925869 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose allogeneic disc progenitor cells
Number of subjects: 60
Study 38925869 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cells
Number of subjects: 60
Study 38926066 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Abiraterone Acetate and Prednisone
Number of subjects: 103
Study 38926068 — intervention group
Group type: EXPERIMENTAL
Intervention: 27.476 IU YF vaccine
Number of subjects: 318
Study 38926068 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.447 IU YF vaccine
Number of subjects: 318
Study 38926068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.013 IU YF vaccine
Number of subjects: 318
Study 38926068 — intervention group
Group type: EXPERIMENTAL
Intervention: 587 IU YF vaccine
Number of subjects: 318
Study 38926068 — intervention group
Group type: EXPERIMENTAL
Intervention: 158 IU YF vaccine
Number of subjects: 318
Study 38926068 — intervention group
Group type: EXPERIMENTAL
Intervention: 31 IU YF vaccine
Number of subjects: 318
Study 38926142 — intervention group
Group type: EXPERIMENTAL
Intervention: exergame and acceptance and commitment therapy (e-ACT) programme
Number of subjects: 126
Study 38926142 — intervention group
Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy (ACT) only
Number of subjects: 126
Study 38926142 — intervention group
Group type: COMPARATOR
Intervention: treatment-as-usual (TAU)
Number of subjects: 126
Study 38926143 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Dementia Care Management (DeCM) delivered by qualified dementia care managers for 6 months.
Number of subjects: 90
Study 38926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine weaning guided by the Hypotension Prediction Index (HPI) with MAP>65 mmHg and HPI<80
Number of subjects: 142
Study 38926148 — intervention group
Group type: COMPARATOR
Intervention: Control group with norepinephrine weaning based solely on MAP>65 mm Hg
Number of subjects: 142
Study 38926148 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine weaning guided by the HPI
Number of subjects: 142
Study 38926162 — intervention group
Group type: EXPERIMENTAL
Intervention: CLDN18.2-targeted nanobody, PMD22, labeled with gallium-68
Number of subjects: 0
Study 38926266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten 15 mg plus activated charcoal 50 g administered 2 h after mavacamten dosing
Number of subjects: 45
Study 38926266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten 15 mg plus activated charcoal 50 g administered 6 h after mavacamten dosing
Number of subjects: 45
Study 38926266 — intervention group
Group type: COMPARATOR
Intervention: Mavacamten 15 mg alone
Number of subjects: 45
Study 38926682 — intervention group
Group type: EXPERIMENTAL
Intervention: HCLD +  (n=287)
Number of subjects: 345
Study 38926682 — intervention group
Group type: COMPARATOR
Intervention: HCLD- (n=58)
Number of subjects: 345
Study 38926682 — intervention group
Group type: EXPERIMENTAL
Intervention: HCLD +  (n=116 positive for SP)
Number of subjects: 345
Study 38926682 — intervention group
Group type: COMPARATOR
Intervention: HCLD- (n=12 positive for SP)
Number of subjects: 345
Study 38926682 — intervention group
Group type: EXPERIMENTAL
Intervention: HCLD + 
Number of subjects: 345
Study 38926693 — intervention group
Group type: EXPERIMENTAL
Intervention: PI*SS genotype
Number of subjects: 1007